183 related articles for article (PubMed ID: 31341642)
1. Transferrin-bearing liposomes entrapping plumbagin for targeted cancer therapy.
Sakpakdeejaroen I; Somani S; Laskar P; Mullin M; Dufès C
J Interdiscip Nanomed; 2019 Jun; 4(2):54-71. PubMed ID: 31341642
[TBL] [Abstract][Full Text] [Related]
2. Anti-Tumor Activity of Intravenously Administered Plumbagin Entrapped in Targeted Nanoparticles.
Sakpakdeejaroen I; Somani S; Laskar P; Irving C; Mullin M; Dufès C
J Biomed Nanotechnol; 2020 Jan; 16(1):85-100. PubMed ID: 31996288
[TBL] [Abstract][Full Text] [Related]
3. Regression of Melanoma Following Intravenous Injection of Plumbagin Entrapped in Transferrin-Conjugated, Lipid-Polymer Hybrid Nanoparticles.
Sakpakdeejaroen I; Somani S; Laskar P; Mullin M; Dufès C
Int J Nanomedicine; 2021; 16():2615-2631. PubMed ID: 33854311
[TBL] [Abstract][Full Text] [Related]
4. Tumor regression after systemic administration of tocotrienol entrapped in tumor-targeted vesicles.
Fu JY; Blatchford DR; Tetley L; Dufès C
J Control Release; 2009 Dec; 140(2):95-9. PubMed ID: 19709637
[TBL] [Abstract][Full Text] [Related]
5. Alpha-Mangostin-Loaded Transferrin-Conjugated Lipid-Polymer Hybrid Nanoparticles: Development and Characterization for Tumor-Targeted Delivery.
Sakpakdeejaroen I; Muanrit P; Panthong S; Ruangnoo S
ScientificWorldJournal; 2022; 2022():9217268. PubMed ID: 36081606
[TBL] [Abstract][Full Text] [Related]
6. Novel tocotrienol-entrapping vesicles can eradicate solid tumors after intravenous administration.
Fu JY; Zhang W; Blatchford DR; Tetley L; McConnell G; Dufès C
J Control Release; 2011 Aug; 154(1):20-6. PubMed ID: 21539872
[TBL] [Abstract][Full Text] [Related]
7. Tumor regression after intravenous administration of targeted vesicles entrapping the vitamin E α-tocotrienol.
Karim R; Somani S; Al Robaian M; Mullin M; Amor R; McConnell G; Dufès C
J Control Release; 2017 Jan; 246():79-87. PubMed ID: 27993600
[TBL] [Abstract][Full Text] [Related]
8. Formulation of plumbagin loaded long circulating pegylated liposomes: in vivo evaluation in C57BL/6J mice bearing B16F1 melanoma.
Kumar MR; Aithal BK; Udupa N; Reddy MS; Raakesh V; Murthy RS; Raju DP; Rao BS
Drug Deliv; 2011; 18(7):511-22. PubMed ID: 21793763
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary delivery of transferrin receptors targeting peptide surface-functionalized liposomes augments the chemotherapeutic effect of quercetin in lung cancer therapy.
Riaz MK; Zhang X; Wong KH; Chen H; Liu Q; Chen X; Zhang G; Lu A; Yang Z
Int J Nanomedicine; 2019; 14():2879-2902. PubMed ID: 31118613
[No Abstract] [Full Text] [Related]
10. Delivery of the vitamin E compound tocotrienol to cancer cells.
Dufès C
Ther Deliv; 2011 Nov; 2(11):1385-9. PubMed ID: 22826870
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of the tea polyphenol epigallocatechin-3-gallate encapsulated in targeted vesicles after intravenous administration.
Lemarié F; Chang CW; Blatchford DR; Amor R; Norris G; Tetley L; McConnell G; Dufès C
Nanomedicine (Lond); 2013 Feb; 8(2):181-92. PubMed ID: 22891867
[TBL] [Abstract][Full Text] [Related]
12. ApoE-2 Brain-Targeted Gene Therapy Through Transferrin and Penetratin Tagged Liposomal Nanoparticles.
Dos Santos Rodrigues B; Kanekiyo T; Singh J
Pharm Res; 2019 Sep; 36(11):161. PubMed ID: 31529284
[TBL] [Abstract][Full Text] [Related]
13. Transferrin-Targeted Liposomes in Glioblastoma Therapy: A Review.
Kawak P; Sawaftah NMA; Pitt WG; Husseini GA
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686065
[TBL] [Abstract][Full Text] [Related]
14. Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer.
Deshpande P; Jhaveri A; Pattni B; Biswas S; Torchilin V
Drug Deliv; 2018 Nov; 25(1):517-532. PubMed ID: 29433357
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid-paclitaxel (CLA-PTX) on B16-F10 melanoma.
Du R; Zhong T; Zhang WQ; Song P; Song WD; Zhao Y; Wang C; Tang YQ; Zhang X; Zhang Q
Int J Nanomedicine; 2014; 9():3091-105. PubMed ID: 25028548
[TBL] [Abstract][Full Text] [Related]
16. Biocompatibility and therapeutic evaluation of magnetic liposomes designed for self-controlled cancer hyperthermia and chemotherapy.
Gogoi M; Jaiswal MK; Sarma HD; Bahadur D; Banerjee R
Integr Biol (Camb); 2017 Jun; 9(6):555-565. PubMed ID: 28513646
[TBL] [Abstract][Full Text] [Related]
17. Surface-modified Epirubicin-HCl liposomes and its in vitro assessment in breast cancer cell-line: MCF-7.
Gandhi R; Khatri N; Baradia D; Vhora I; Misra A
Drug Deliv; 2016 May; 23(4):1152-62. PubMed ID: 25586675
[TBL] [Abstract][Full Text] [Related]
18. Tumor regression after systemic administration of a novel tumor-targeted gene delivery system carrying a therapeutic plasmid DNA.
Koppu S; Oh YJ; Edrada-Ebel R; Blatchford DR; Tetley L; Tate RJ; Dufès C
J Control Release; 2010 Apr; 143(2):215-21. PubMed ID: 19944722
[TBL] [Abstract][Full Text] [Related]
19. Enhanced Efficacy of Artemisinin Loaded in Transferrin-Conjugated Liposomes versus Stealth Liposomes against HCT-8 Colon Cancer Cells.
Leto I; Coronnello M; Righeschi C; Bergonzi MC; Mini E; Bilia AR
ChemMedChem; 2016 Aug; 11(16):1745-51. PubMed ID: 26999297
[TBL] [Abstract][Full Text] [Related]
20. Intracellular targeting of sodium mercaptoundecahydrododecaborate (BSH) to solid tumors by transferrin-PEG liposomes, for boron neutron-capture therapy (BNCT).
Maruyama K; Ishida O; Kasaoka S; Takizawa T; Utoguchi N; Shinohara A; Chiba M; Kobayashi H; Eriguchi M; Yanagie H
J Control Release; 2004 Aug; 98(2):195-207. PubMed ID: 15262412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
